en.Wedoany.com Reported - Senseonics Holdings, Inc. recently presented new data from a large-scale real-world evidence study of its Eversense 365 implantable continuous glucose monitoring (CGM) system at the American Diabetes Association (ADA) 2026 Scientific Sessions. The study demonstrated sustained accuracy, high performance, and positive patient outcomes in both open-loop and closed-loop (integrated with automated insulin delivery system AID) usage scenarios.
The data released at ADA expands on findings the company shared earlier this year at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), with the dataset incorporating more Eversense 365 sensors and users. The research team conducted a real-world analysis of the first 12,360 Eversense 365 CGM sensors (used by open-loop users) and an additional 153 closed-loop users (who used the CGM as part of the twiist AID system for over 30 days).
The data confirmed that Eversense 365 has a positive impact in the real world, with patients maintaining high adherence, favorable glycemic metrics, and low hypoglycemia outcomes throughout the year. Notably, the system demonstrated comparable adherence and outcomes during the first six months and the last six months, validating the high accuracy and performance of a single sensor over the entire year. The report also highlighted robust glycemic metrics from the Eversense 365 and twiist combination, indicating that this first-of-its-kind integration of a unique CGM with an AID system is delivering meaningful clinical impact for patients.
Among open-loop insulin regimen users, the average transmitter wear time for the 12,360 sensors reached 93.19%. Users had an average glucose management indicator (GMI) of 7.16% and an average time in range (TIR) of 66.16%. This TIR metric compares favorably to real-world reports from other CGM systems (ranging from 41.7% to 70.8%). Additionally, over 81% of Eversense 365 users achieved hypoglycemia targets, outperforming other CGM systems. Data showed that Eversense 365 maintained high accuracy in the hypoglycemic range, where errors have the greatest impact on patient safety and treatment decisions.
Among users integrated with the twiist AID system, data from 153 sensors showed that users achieved an average TIR of approximately 76.08% and a GMI of 6.78% within the first 30 days after pump pairing, with a median sensor wear time of up to 99.46%. Compared to large-scale real-world data from existing AID systems, the Eversense 365 integration performed at the high end of the reported performance ranges for TIR (approximately 52.5%-78.8%) and GMI (6.9%-7.9%). These findings indicate that the combination of Eversense 365 and twiist helps patients achieve glycemic goals and improve diabetes management.
Francine Kaufman, M.D., Chief Medical Officer of Senseonics, stated that the analysis shows Eversense 365 provides consistent and tangible benefits for users of open-loop or closed-loop systems, giving patients and healthcare providers more choice and confidence when using this differentiated CGM. Brian Hansen, Chief Commercial Officer, added that the ability of a single CGM sensor to maintain consistent performance in both the first and second halves of the year validates the company's current technology foundation in the market, as well as the product pipeline based on the same scientific principles.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
